Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$49.31 USD
+0.22 (0.45%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $49.78 +0.47 (0.95%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$49.31 USD
+0.22 (0.45%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $49.78 +0.47 (0.95%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Zacks News
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
by Ekta Bagri
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
by Zacks Equity Research
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of 21.43% and 1.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -0.43% and 5.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 0% and 5.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline
by Zacks Equity Research
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals, Inc. (RYTM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?
by Zacks Equity Research
Puma Biotech (PBYI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 0% and 2.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Rhythm Pharmaceuticals, Inc. (RYTM) Could Rally 53.81%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 53.8% in Rhythm Pharmaceuticals, Inc. (RYTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -2.50% and 29.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -29.58% and 2.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 8.54% and 24.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 21.78% and 20.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Solid Biosciences Inc. (SLDB) Q3 Earnings Expected to Decline
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study
by Zacks Equity Research
Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.
Akero Therapeutics (AKRO) Up on Positive NASH Study Data
by Zacks Equity Research
Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.